Table 4 Validation of different stabilizing effects of ligand binding on thermal stability of dihydrofolate reductases.
Clinically Relevant DHFR Ti (°C) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Â | EcDHFR | DfrA1 | DfrA5 | |||||
Ti 1 | Δ1 | Ti 2 | Δ2 | Ti | Δ | Ti | Δ | |
Apo | 49.6 ± 0.6 | – | 60.2 ± 0.3 | – | 49.8 ± 0.5 | – | 66.3 ± 0.5 | – |
+NADPH | 53.8 ± 0.4 | 4.2 | 63.1 ± 1.3 | 2.9 | 56.5 ± 0.8 | 6.7 | 69.2 ± 0.5 | 2.9 |
+TMP | 67.1 ± 2.0 | 17.5 | 74.1 ± 0.5 | 13.9 | 52.3 ± 0.3 | 2.5 | 66.8 ± 0.7 | 0.5 |
+NADPH, +TMP | – | – | 77.1 ± 0.5 | 16.9 | 62.3 ± 0.2 | 12.5 | 72.6 ± 0.3 | 6.3 |
+UCP1223 | 68.5 ± 1.4 | 18.9 | 80.8 ± 0.2 | 20.6 | 58.5 ± 0.1 | 8.7 | 67.3 ± 1.0 | 1.0 |
+NADPH, +UCP1223 | 78.9 ± 2.4 | 29.3 | 88.3 ± 0.5 | 28.1 | 71.2 ± 3.1 | 21.4 | 88.5 ± 0.2 | 22.2 |
+UCP1228 | 65.5 ± 4.6 | 15.9 | 76.5 ± 2.5 | 16.3 | 55.4 ± 1.7 | 5.6 | 70. 0 ± 2.7 | 3.7 |
+NADPH, +UCP1228 | 64.3 ± 0.1 | 14.7 | 75.7 ± 1.6 | 15.5 | 66.5 ± 3.3 | 16.7 | 77.3 ± 4.7 | 11 |